Recombinant Human C1s protein, His-tagged

• Cat.No.: C1S-597H
• Product Overview: Recombinant Human C1s protein(NP_001725.1)(Met1-Asp688), fused with His tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Human
• Tag: His
• Form: Lyophilized from sterile PBS, pH 7.4.Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human C1s protease consists of 684 amino acids and has a predicted molecular mass of 76.3 kDa. As a result of glycosylation, rhC1s migrates as an approximately 82.06 kDa, 56.59 kDa and 33.36 kDa band in SDS-PAGE under reducing conditions.
• Protein Length: Met1-Asp688
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 90 % as determined by SDS-PAGE. >90% as determined by SEC-HPLC
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C
  Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: C1S complement component 1, s subcomponent [ Homo sapiens ]
• Official Symbol: C1s
• Synonyms: C1S; complement component 1, s subcomponent; complement C1s subcomponent; C1 esterase; basic proline-rich peptide IB-1; complement component 1 subcomponent s; FLJ44757
• Gene ID: 716
• mRNA Refseq: NM_001734
• Protein Refseq: NP_001725
• MIM: 120580
• UniProt ID: P09871

Reviews

12/07/2018

This level of sensitivity and specificity has streamlined my research and allowed for precise protein characterization.

09/28/2018

The protein bands detected were exceptionally distinct, enabling easy interpretation and accurate analysis of protein expression patterns.

09/16/2018

To summarize, the C1S protein is a highly recommended asset for various research endeavors, including ELISA, protein electron microscopy structure analysis, and Western blotting.

Q&As

Is C1S protein deficiency a rare condition?

Yes, C1S protein deficiency is rare, but it is more common in patients with a family history of HAE.

What are the potential side effects or risks associated with C1S replacement therapy?

Side effects can include infusion site reactions or hypersensitivity reactions, so treatment is typically administered under medical supervision.

How is C1S protein replacement therapy administered to patients with HAE?

C1S protein replacement therapy is usually given intravenously, and the frequency of administration may vary depending on the patient's needs.

Can C1S protein be used in the treatment of conditions other than HAE?

C1S replacement therapy is primarily used for HAE, but researchers are investigating its potential use in other complement-related disorders.

Are there any ongoing research efforts related to C1S protein in clinical applications?

Yes, ongoing research aims to better understand the role of C1S in HAE and explore new treatment options, such as gene therapy.